Showing posts with label transplant. Show all posts
Showing posts with label transplant. Show all posts

Sunday, July 29, 2012

Teen Doing Well 2 Years After Stem Cell Windpipe Transplant

HealthDay – 1 hr 12 mins ago WEDNESDAY, July 25 (HealthDay News) -- Two years after he became the first child to receive a stem cell-supported trachea (windpipe) transplant, a 13-year-old boy is able to breathe normally, has grown about four inches taller, does not require any anti-rejection drugs and has returned to school.

Ciaran Finn-Lynch, born with a structural defect of his large airway, underwent the transplant in March 2010 at Great Ormond Street Hospital in London. After his windpipe was removed, it was replaced by a windpipe from a deceased donor in Italy.

The windpipe was stripped of the donor's cells down to the inert structure of collagen. Tissue from the lining of Finn-Lynch's windpipe was implanted in the new windpipe to kick-start the growth of a lining in the new windpipe.

The surgeons laced the transplanted windpipe with Finn-Lynch's own bone marrow stem cells to prevent his body from rejecting the new organ. The teen also received compounds to promote the growth and differentiation of cells within the new windpipe.

It was the first attempt to grow stem cells within the body of a child who had this type of operation, rather than in a laboratory, according to an article published online July 25 in The Lancet.

"Since the treatment plan for Ciaran was devised in an emergency, we used a novel mix of techniques that have proved successful in treating other conditions," paper co-author Martin Birchall, a professor of laryngology at University College London's Ear Institute, said in a journal news release. "To minimize delays, we bypassed the usual process of growing cells in the laboratory over a period of weeks, and instead opted to grow the cells inside the body, in a similar manner to treatments currently being (tested) with patients who have had heart attacks."

He added that more research is needed on stem cells grown deliberately inside the body, rather than grown first in a laboratory over a long time. "This research should help to convert one-off successes such as this into more widely available clinical treatments for thousands of children with severe tracheal problems worldwide," he said.

More information

The U.S. National Institutes of Health has more about stem cells.



View the Original article

Friday, July 13, 2012

HIV Drug May Prevent Bone Marrow Transplant Complication

HealthDay – 1 hr 3 mins ago WEDNESDAY, July 11 (HealthDay News) -- An HIV drug significantly reduced the risk of graft-versus-host disease, an all-too-common complication in blood cancer patients following bone marrow transplants, new research finds.

Bone marrow is the spongy tissue inside the bones that contains immature cells, or stem cells. In an "allogeneic" bone marrow transplantation, also called a stem cell transplant, a patient's own stem cells and immune system are wiped out by chemotherapy and radiation. Then, the patient receives the transplant, or bone marrow, from a closely matched donor.

The treatment is used for several types of blood cancers, including lymphoma and leukemia.

But a common complication of a bone marrow transplant is graft-versus-host disease. It occurs when transplanted immune cells attack patients' healthy tissue, a complication that can be minor or life-threatening.

"Graft-versus-host disease affecting the skin, liver, gut and other organs is a dreaded complication of allogeneic stem cell transplantation either from a related or unrelated donor," said one expert, Dr. Jasmine Zain of NYU Langone Medical Center in New York City. "The rates are 35 percent with related donors and up to 57 percent by day 100, even in reduced-intensity transplants," added Zain, who is director of the Bone Marrow Transplant Program and assistant professor in the division of hematologic malignancies and medical oncology at the center.

The study was conducted by a team at the University of Pennsylvania's Perelman School of Medicine and included 38 patients with several types of blood cancers. The cancers included acute myeloid leukemia, myelodysplastic syndrome, lymphoma and myelofibrosis. All of the patients were given the drugs tacrolimus and methotrexate, which suppress the immune system and are a standard treatment to prevent graft-versus-host disease.

The patients were also given a 33-day course of the HIV drug, maraviroc, beginning two days before their transplant.

None of the patients treated with maraviroc developed graft-versus-host disease in the gut or liver within the first 100 days after their transplant. The liver and gut are the most serious locations for the complication, the researchers noted.

After six months, 6 percent of these transplant patients developed severe graft-versus-host disease compared to 22 percent of a group of similar patients who weren't treated with the HIV drug.

In addition, fewer in the group given the HIV drug developed graft-versus-host disease in their liver or gut compared to those given the standard treatment.

One year following transplant, about 15 percent of patients given the HIV drug developed severe graft-versus-host disease compared to 29 percent of patients who received standard therapy.

The study was published in the July 11 edition of the New England Journal of Medicine.

Researchers explained that the HIV drug redirects these immune cells without having to suppress patients' immune systems. Because their immune systems aren't compromised by the drug, patients should be less vulnerable to infections and to a relapse of their cancer.

"It appears that our new approach allows us to prevent some patients from developing

View the Original article

Thursday, July 12, 2012

HIV Drug May Prevent Bone Marrow Transplant Complication

HealthDay – 1 hr 2 mins ago WEDNESDAY, July 11 (HealthDay News) -- An HIV drug significantly reduced the risk of graft-versus-host disease, an all-too-common complication in blood cancer patients following bone marrow transplants, new research finds.

Bone marrow is the spongy tissue inside the bones that contains immature cells, or stem cells. In an "allogeneic" bone marrow transplantation, also called a stem cell transplant, a patient's own stem cells and immune system are wiped out by chemotherapy and radiation. Then, the patient receives the transplant, or bone marrow, from a closely matched donor.

The treatment is used for several types of blood cancers, including lymphoma and leukemia.

But a common complication of a bone marrow transplant is graft-versus-host disease. It occurs when transplanted immune cells attack patients' healthy tissue, a complication that can be minor or life-threatening.

"Graft-versus-host disease affecting the skin, liver, gut and other organs is a dreaded complication of allogeneic stem cell transplantation either from a related or unrelated donor," said one expert, Dr. Jasmine Zain of NYU Langone Medical Center in New York City. "The rates are 35 percent with related donors and up to 57 percent by day 100, even in reduced-intensity transplants," added Zain, who is director of the Bone Marrow Transplant Program and assistant professor in the division of hematologic malignancies and medical oncology at the center.

The study was conducted by a team at the University of Pennsylvania's Perelman School of Medicine and included 38 patients with several types of blood cancers. The cancers included acute myeloid leukemia, myelodysplastic syndrome, lymphoma and myelofibrosis. All of the patients were given the drugs tacrolimus and methotrexate, which suppress the immune system and are a standard treatment to prevent graft-versus-host disease.

The patients were also given a 33-day course of the HIV drug, maraviroc, beginning two days before their transplant.

None of the patients treated with maraviroc developed graft-versus-host disease in the gut or liver within the first 100 days after their transplant. The liver and gut are the most serious locations for the complication, the researchers noted.

After six months, 6 percent of these transplant patients developed severe graft-versus-host disease compared to 22 percent of a group of similar patients who weren't treated with the HIV drug.

In addition, fewer in the group given the HIV drug developed graft-versus-host disease in their liver or gut compared to those given the standard treatment.

One year following transplant, about 15 percent of patients given the HIV drug developed severe graft-versus-host disease compared to 29 percent of patients who received standard therapy.

The study was published in the July 11 edition of the New England Journal of Medicine.

Researchers explained that the HIV drug redirects these immune cells without having to suppress patients' immune systems. Because their immune systems aren't compromised by the drug, patients should be less vulnerable to infections and to a relapse of their cancer.

"It appears that our new approach allows us to prevent some patients from developing

View the Original article

Friday, June 29, 2012

Surgeons Seek Repeal of Transplant Ban Between HIV-Positive People

background:url(http://l.yimg.com/a/p/us/news/editorial/a/5b/a5ba32682eb601fb573b57542c19b9c1.png);width:115px;height:25px;margin-left:50px;margin-top:7px

View the Original article

Thursday, June 28, 2012

Surgeons Seek Repeal of Transplant Ban Between HIV-Positive People

background:url(http://l.yimg.com/a/p/us/news/editorial/a/5b/a5ba32682eb601fb573b57542c19b9c1.png);width:115px;height:25px;margin-left:50px;margin-top:7px

View the Original article

Monday, June 25, 2012

Skin Cell Transplant May Offer New Hope to Vitiligo Patients

background:url(http://l.yimg.com/a/p/us/news/editorial/a/5b/a5ba32682eb601fb573b57542c19b9c1.png);width:115px;height:25px;margin-left:50px;margin-top:7px

View the Original article

Sunday, June 10, 2012

More Hispanics die waiting for a heart transplant

"background-image:url('http://l2.yimg.com/bt/api/res/1.2/ZLEhl173G6GBNIY2j.sutw--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTcwO3B5b2ZmPTA7cT04NTt3PTcw/http://media.zenfs.com/en_us/News/Reuters/2012-06-07T121110Z_1_CBRE8560XUW00_RTROPTP_2_AFGHANISTAN-PIRTLEKING.JPG');" width

View the Original article

Monday, April 2, 2012

Face transplant patient can feel daughter's kisses

'modId':'mediatabs_nmid_1_conv_prom','isPreLoad':0,'enableMediaTabEvent':0,'pageSize':12,'numFriends':null,'notificationCount':0,'property':'News','learnMorePath':'/activity-learn-more/','friendbarNotification':'0','moduleConf':YAHOO.Media.Facebook.ModuleConf,'friendIdList':

View the Original article

Photos: How Face Transplant Changed Dallas Wiens' Life

WARNING: Some of the following pictures are of a graphic nature. Viewer discretion is advised. (ABC News) Like It. Tweet It. Digg It. ABC News on FacebookSlideshows

View the Original article

Wednesday, March 28, 2012

US man gets 'most extensive' face transplant ever

'modId':'mediatabs_nmid_1_conv_prom','isPreLoad':0,'enableMediaTabEvent':0,'pageSize':12,'numFriends':null,'notificationCount':0,'property':'News','learnMorePath':'/activity-learn-more/','moduleConf':YAHOO.Media.Facebook.ModuleConf,'friendIdList':

View the Original article

Sunday, March 25, 2012

Cheney gets heart transplant, in intensive care

"background-image:url('http://l.yimg.com/bt/api/res/1.2/kYSUL99.ZMiY82N5nGf9JA--/YXBwaWQ9eW5ld3M7Y2g9Mjg3O2NyPTE7Y3c9NDUwO2R4PTA7ZHk9MDtmaT11bGNyb3A7aD0xMjI7cT04NTt3PTE5MA--/http://media.zenfs.com/en_us/News/Reuters/2012-03-25T000940Z_1_CBRE82N1TC800_RTROPTP_2_USA-POLITICS-REPUBLICANS.JPG');" width

View the Original article

Aide says Cheney had heart transplant

"background-image:url('http://l.yimg.com/bt/api/res/1.2/iIdLaGAFCnXYf3Eku175ew--/YXBwaWQ9eW5ld3M7Y2g9MzYwO2NyPTE7Y3c9NjQwO2R4PTA7ZHk9MDtmaT11bGNyb3A7aD0xMDc7cT04NTt3PTE5MA--/http://media.zenfs.com/en_us/News/us.news.abcnews.otus/abc_dick_cheney_jon_karl_mw_110907_wmain.jpg');" width

View the Original article